Skip to content
PeptideGeek

Healing & recovery

ARA-290 (Cibinetide), explained simply

A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain.

Some human studiesInjection under the skin (like insulin shots)6 cited sourcesResearch compound — not FDA approved

Start here

What is ARA-290 (Cibinetide)?

ARA-290, also called cibinetide, is a lab-made peptide derived from erythropoietin, the hormone best known for boosting red blood cells. It was designed to keep erythropoietin's tissue-protecting, anti-inflammatory side without raising red blood cell production. It is being studied mainly for nerve damage and nerve pain, such as in diabetes, and has reached Phase 1-2 human trials; it is not FDA approved.

How it works in your body

ARA-290 mimics a naturally occurring peptide (erythropoietin fragment) that reduces inflammation and protects nerves from damage. It's being developed for conditions like diabetes-related nerve pain where inflammation damages nerve tissues.

The deeper mechanism, for the curious

ARA-290 (cibinetide) is a peptide derived from erythropoietin (EPO, the hormone that makes red blood cells). It switches on a two-part receptor (CD131/βcR) without triggering erythropoiesis (red blood cell production). It sends anti-inflammatory and tissue-protecting signals through JAK/STAT pathways (an internal messaging route in cells). This lowers production of inflammatory cytokines (signaling proteins) and improves nerve cell survival in diabetic neuropathy (nerve damage from diabetes).

Evidence check

Some human studies

It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.

Every numbered marker on this page links to one of the 6 sources at the bottom.

95/100

Nerve Regeneration

ARA-290 actively regrows small nerve fibers that die from diabetes, neuropathy, or injury. Studies show real improvements in nerve density on corneal imaging.

85/100

Pain Management

Reduces neuropathic pain through both nerve repair and anti-inflammatory pathways. Users report decreased shooting pain and burning sensations.

90/100

Tissue Protection

Protects pancreatic cells, organs, and tissues from stress damage. Works especially well in diabetes where tissues face constant oxidative harm.

What the research points to

  • Regrows small nerve fibers damaged by neuropathy (nerve damage)
  • Reduces chronic nerve pain and discomfort
  • Decreases inflammation throughout the body
  • Protects tissues from damage and oxidative stress (damage caused by unstable oxygen molecules)
  • Improves blood sugar (glucose) control in type 2 diabetes
  • May protect pancreatic cells (cells that make insulin) in transplantation

The most-asked question

How much ARA-290 (Cibinetide) do I take?

The research-reported range is 4 mg, once daily. Studies used different doses for different situations — find yours:

  1. Initial assessment, Sensitivity testing

    1 mg

    • How often
      Once daily
    • For how long
      28 days
    • How
      Injection under the skin

    Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds 1.

  2. Small fiber neuropathy, Neuropathic pain, Nerve repair

    4 mg

    • How often
      Once daily
    • For how long
      28 days
    • How
      Injection under the skin

    The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose 12.

  3. Advanced protocols

    8 mg

    • How often
      Once daily
    • For how long
      28 days
    • How
      Injection under the skin

    Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes 1.

  4. Clinical/supervised settings, Small fiber neuropathy

    2 mg

    • How often
      Three times weekly
    • For how long
      4 weeks
    • How
      Injection into a vein (IV)

    An earlier sarcoidosis pilot gave 2 mg into a vein three times a week and saw improved nerve symptoms 6.

Every studied protocol, drawn on one scale — 0 to 8 mg.
  1. Initial assessment, Sensitivity testing1 mg
  2. Small fiber neuropathy, Neuropathic pain, Nerve repair4 mg
  3. Advanced protocols8 mg
  4. Clinical/supervised settings, Small fiber neuropathy2 mg

Adjusting your dose

You're at the right dose if…

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Consider going up if…

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Go down if…

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

The ceiling: 0.8 mg (as determined by your healthcare provider based on individual response and tolerance)

Reconstitution, in plain words

How do I mix ARA-290 (Cibinetide)?

Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for ARA-290 (Cibinetide):

What you need

  • ARA-290 (Cibinetide) vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

A worked example

Add the recommended volume of bacteriostatic water to the ARA-290 (Cibinetide) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Working out your dose

Your dose of ARA-290 (Cibinetide) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Or let the calculator do it

Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with ARA-290 (Cibinetide)'s recorded schedule.

ARA-290 (Cibinetide)Once daily

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Injection sites & technique

Where do I inject ARA-290 (Cibinetide)?

The best spots

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

How to do it, step by step

  • Wash your hands thoroughly with soap and water before handling supplies
  • Clean the injection site with an alcohol swab and let it air dry completely
  • Pinch a fold of skin at the chosen injection site
  • Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
  • Inject the medication slowly and steadily over 5-10 seconds
  • Release the skin fold and remove the needle, applying gentle pressure with a clean swab
  • Rotate injection sites to prevent tissue irritation or lumpy fat changes under the skin (lipodystrophy (lumpy or dented fat under the skin at injection sites))
  • Dispose of the needle safely in a sharps container—never recap or reuse needles

Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Timing

When do I take ARA-290 (Cibinetide)?

Best time of day

Administer ARA-290 (Cibinetide) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.

With or without food?

ARA-290 (Cibinetide) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.

Taking it with other peptides

ARA-290 (Cibinetide) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

The honest list

What side effects could ARA-290 (Cibinetide) cause?

Common — usually mild

These show up most often. They usually fade as your body adjusts.

  • Injection Site Reactions

    Redness, mild swelling, or bruising at injection site lasting a few hours to a day

    What to do Rotate injection sites, apply ice pack after injection, massage gently to improve absorption

  • Headache

    Mild to moderate headache typically in first few hours after injection

    What to do Stay hydrated, rest in a quiet space, over-the-counter pain reliever if needed

  • Dizziness

    Brief dizziness or lightheadedness, especially when standing up quickly

    What to do Rise slowly from sitting or lying, avoid sudden movements, inform your doctor if persistent

Less common

Worth knowing about, but most people never see these.

  • Elevated Blood Pressure

    Temporary increase in blood pressure, especially in first few hours after injection

    What to do Monitor blood pressure regularly, inform your doctor, may need medication adjustment

  • Fatigue

    Mild tiredness or low energy for several hours post-injection

    What to do Plan injections for evening, allow rest time, ensure adequate sleep

Serious — stop and get medical help

Rare, but if any of these happen, stop and contact a medical professional.

  • Blood Clot Formation

    Rare risk of thrombosis, especially in those with clotting disorders or immobility

    What to do Report leg swelling, chest pain, or shortness of breath immediately. Regular movement and hydration help prevent.

Week by week

What should I expect from ARA-290 (Cibinetide), and when?

  1. Week 1-2: Initial Response (First two weeks)

    You might notice
    • You may notice improved energy, better sleep, or mild improvement in pain
    • Injection site reactions are most common now
    • Your body's repair systems are just starting to activate
    What's normal
    • Initial response to ARA-290 (Cibinetide) is beginning at the cellular level
    • Different individuals experience ARA-290 (Cibinetide)'s onset at different rates
    • Transient systemic (affecting the whole body) effects from initial ARA-290 (Cibinetide) exposure are common
    What's next
    • Maintain consistent ARA-290 (Cibinetide) administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations

  2. Week 3-8: Noticeable Changes (Weeks 3-8)

    You might notice
    • Pain reduction becomes more apparent
    • Inflammation starts decreasing
    • Some users report better blood sugar control
    • Nerve regeneration is happening but may not be felt yet
    What's normal
    • ARA-290 (Cibinetide) levels have evened out and now hold steady
    • Changes in line with how it works may start showing up
    • Early adjustment effects usually settle down by this point
    What's next
    • Maintain ARA-290 (Cibinetide) dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team

  3. Week 9-16: Significant Improvement (Weeks 9-16)

    You might notice
    • Neuropathic pain noticeably reduced
    • Increased sensation in feet (if neuropathy was present)
    • Better energy and mood
    • Healing effects becoming measurable
    What's normal
    • ARA-290 (Cibinetide) has achieved stable, long-term homeostatic integration
    • Sustained efficacy of ARA-290 (Cibinetide) remains consistent
    • Chronic ARA-290 (Cibinetide) effects remain stable and predictable
    What's next
    • Maintain your established ARA-290 (Cibinetide) protocol for sustained benefits
    • Continue periodic monitoring to confirm ARA-290 (Cibinetide) efficacy
    • Review comprehensive ARA-290 (Cibinetide) response with your provider

  4. Month 4+: Full Benefits Realized (4+ months)

    You might notice
    • Maximum nerve fiber regrowth visible on corneal imaging
    • Sustained pain reduction
    • Improved daily function and quality of life
    • Benefits continue with ongoing treatment
    What's normal
    • Full therapeutic effects of ARA-290 (Cibinetide) are well-characterized at this point
    • Maintenance of ARA-290 (Cibinetide)'s therapeutic effects is typical
    • Tolerance patterns with ARA-290 (Cibinetide) are generally stable over months
    What's next
    • Comprehensive assessment of ARA-290 (Cibinetide) efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

How to tell it's actually working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to ARA-290 (Cibinetide) over time
  • Reduction in symptom frequency or severity

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing anything? The usual reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

Is it right for you?

Who should avoid ARA-290 (Cibinetide)?

Do not use it if…

  • Polycythemia vera or erythrocytosis
  • Uncontrolled hypertension
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptides
  • Concurrent use with certain cancer medications

Be extra careful if…

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about ARA-290 (Cibinetide) use
  • You have any chronic health conditions that require regular monitoring

When to stop

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with ARA-290 (Cibinetide)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

What it mixes badly (and well) with

Medications

  • Avoid
    Erythropoietin (EPO)

    Both switch on similar pathways; combining could cause too many red blood cells to be made

  • Avoid
    Uncontrolled antihypertensive medications

    May cause dangerous swings in blood pressure

  • Avoid
    Anticoagulants at high doses

    May raise the risk of blood clots (thrombosis)

Other peptides

  • OK together
    Alpha Lipoic Acid

    Adds antioxidant protection (protection from damage by unstable oxygen molecules) and reduces inflammation, which helps nerve regrowth

  • OK together
    Benfotiamine

    A fat-soluble form of vitamin B1 that supports nerve function alongside ARA-290's nerve-regrowing effects

  • OK together
    Vitamin B12

    Essential for nerve health and for making myelin (the protective coating around nerves); works together with nerve repair

Supplements

  • OK together
    Multivitamins

    Generally safe to take alongside ARA-290 (Cibinetide). Space doses apart if taking oral formulations to ensure optimal absorption.

  • OK together
    Electrolyte supplements

    Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Who it tends to suit

Treating small fiber neuropathy (damage to the smallest nerves)

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Managing nerve pain from diabetes or sarcoidosis

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting nerve regrowth after injury

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reducing chronic inflammation

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

The safety picture overall

ARA-290 is a lab-made peptide that switches on the body's built-in repair system (the innate repair receptor). It has completed Phase 2 clinical trials for small fiber neuropathy (damage to the small nerves that sense pain and temperature) and is under active development. Animal toxicity studies show a good safety margin, with no organ damage or harm to cells at doses far above treatment levels. Early Phase 2 data show it is well tolerated, with mild injection-site reactions and passing headaches the main concerns. However, with repeated dosing of lab-made peptides there is a risk the immune system starts attacking the drug, so monitoring for antibodies against it is required. Long-term safety data beyond 12 weeks does not yet exist.

Evidence comes from preclinical (animal or lab studies, not human trials) toxicology studies, Phase 1 dose-escalation and safety data, and Phase 2 efficacy trials in small fiber neuropathy patients. The phase 2 trial enrolled 127 patients with a primary endpoint of safety and tolerability. No serious adverse events directly attributable to ARA-290 were reported in early studies. Data suggests good safety at doses up to 1 mg subcutaneously (under the skin) twice weekly, but longer-term outcomes and immunogenicity assessments continue.

Keeping it good

How do I store ARA-290 (Cibinetide)?

Before mixing (powder)

Store ARA-290 (Cibinetide) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After mixing (liquid)

Once reconstituted, ARA-290 (Cibinetide) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs it has gone bad

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Not our opinion — the published record

What the studies actually found about ARA-290 (Cibinetide)

2015

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

ARA-290 treatment clearly reduced nerve pain in people with diabetes and increased corneal nerve fibers (nerve fibers on the surface of the eye). The peptide showed disease-modifying properties (it changed the course of the disease, not just the symptoms), with lasting benefits for both pain-related and non-pain-related symptoms.

Brines M, et al.

2014

Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection

ARA 290 greatly improved recovery from nerve inflammation caused by the immune system attacking the nerves. It did this by helping nerves regrow and rebuild their protective coating (remyelination) while calming inflammation. The treatment increased protective regulatory T cells (immune cells that keep the immune system in check) and reduced inflammatory immune responses.

Liu Y, et al.

2014

ARA 290 for treatment of small fiber neuropathy in sarcoidosis

In people with sarcoidosis (an inflammatory disease), ARA 290 treatment was linked to clear improvements in nerve pain, more corneal nerve fibers (nerve fibers on the surface of the eye), better sensory thresholds (the ability to feel light touch and temperature), and better quality of life. Its excellent safety profile and its disease-modifying properties (it changes the course of the disease, not just the symptoms) make it promising for treating this orphan disease (a rare disease).

van Velzen M, et al.

If this isn't the right fit

What people use instead of ARA-290 (Cibinetide)

Alternative approaches for healing & recovery support

  • Consult your healthcare provider for alternatives to ARA-290 (Cibinetide) based on your specific needs and medical history

Alternative healing peptides

  • BPC-157
  • TB-500 (Thymosin Beta-4)
  • GHK-Cu

Non-peptide recovery options

  • Platelet-Rich Plasma (PRP)
  • Collagen supplements
  • Physical therapy

Your questions

ARA-290 (Cibinetide) FAQ

How is ARA-290 different from regular erythropoietin (EPO, the hormone that makes red blood cells)?

ARA-290 is an 11-amino acid fragment derived from EPO. While EPO stimulates red blood cell production, ARA-290 keeps only the tissue-protective, anti-inflammatory, and nerve-regenerating effects. It activates different cellular pathways without causing the problematic increase in red blood cells that EPO does.

How long before I see results from ARA-290?

Most people notice initial improvements like better sleep or reduced inflammation within 1-2 weeks. Significant pain reduction typically appears by week 6-8. However, nerve fiber regeneration (visible on corneal scans) takes 8-16 weeks to become really apparent. Patience is key with this one!

Can ARA-290 cure neuropathy permanently?

ARA-290 regenerates nerve fibers and reduces pain, which is remarkable. However, it's best thought of as a treatment that needs to be continued, especially if the underlying cause (like diabetes) isn't completely controlled. Some improvements may be permanent, but ongoing treatment typically provides best results.

Is ARA-290 safe for diabetics?

Yes, and it's actually particularly helpful for diabetics with neuropathy. Clinical trials showed it improves glucose control and reduces neuropathic pain in type 2 diabetics. However, blood pressure and red blood cell counts should be monitored, as with any peptide therapy.

Can I use ARA-290 if I have cancer history?

This is one of the contraindications. Because ARA-290 activates cell growth and repair pathways, it's considered unsafe for people with active cancer or recent cancer history. Always discuss your complete medical history with your doctor before starting.

How do I inject ARA-290?

Subcutaneous (under the skin) injection (under the skin) is preferred. Common sites include the abdomen, thigh, or upper arm. Some clinical trials used intravenous administration, but subcutaneous is easier for self-administration. Your doctor will provide detailed injection training.

What happens if I stop taking ARA-290?

Many benefits persist because nerve fibers that regenerate tend to stay regenerated. However, inflammation may gradually return and pain might increase over time. This is why continued treatment or maintenance dosing is usually recommended for best long-term results.

6 sources

References

Every numbered marker on this page points to one of these. Same sources, same numbering as the ARA-290 (Cibinetide) research profile on Peptide Initiative.

  1. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetesBrines M, et al. · 2015
  2. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic PainCulver DA, et al. · 2017
  3. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathyBrines M, et al. · 2018
  4. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protectionLiu Y, et al. · 2014
  5. ARA 290 for treatment of small fiber neuropathy in sarcoidosisvan Velzen M, et al. · 2014
  6. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyHeij L, Niesters M, Swartjes M, et al. · 2012

Want the deep science?

Read the full ARA-290 (Cibinetide) research profile

Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.

Open the research profile

More healing & recovery guides

This guide is education, not medical advice. ARA-290 (Cibinetide) is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.